CN118750659B - Preparation method of hydrogel with tissue repair and antioxidation functions and hydrogel thereof - Google Patents
Preparation method of hydrogel with tissue repair and antioxidation functions and hydrogel thereof Download PDFInfo
- Publication number
- CN118750659B CN118750659B CN202411241750.8A CN202411241750A CN118750659B CN 118750659 B CN118750659 B CN 118750659B CN 202411241750 A CN202411241750 A CN 202411241750A CN 118750659 B CN118750659 B CN 118750659B
- Authority
- CN
- China
- Prior art keywords
- recombinant human
- collagen
- human type
- solution
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 72
- 230000017423 tissue regeneration Effects 0.000 title claims abstract description 12
- 230000006870 function Effects 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 230000003064 anti-oxidating effect Effects 0.000 title abstract description 9
- 102000012422 Collagen Type I Human genes 0.000 claims abstract description 40
- 108010022452 Collagen Type I Proteins 0.000 claims abstract description 40
- 102000001187 Collagen Type III Human genes 0.000 claims abstract description 40
- 108010069502 Collagen Type III Proteins 0.000 claims abstract description 40
- 229920001661 Chitosan Polymers 0.000 claims abstract description 27
- 229930182490 saponin Natural products 0.000 claims abstract description 26
- 150000007949 saponins Chemical class 0.000 claims abstract description 26
- 235000017709 saponins Nutrition 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 18
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 18
- 208000027418 Wounds and injury Diseases 0.000 claims description 23
- 230000006378 damage Effects 0.000 claims description 18
- 208000014674 injury Diseases 0.000 claims description 11
- 210000004696 endometrium Anatomy 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 208000028685 Asherman syndrome Diseases 0.000 claims description 5
- 201000001389 adhesions of uterus Diseases 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 claims description 2
- 238000010008 shearing Methods 0.000 claims description 2
- VZLZTLCFXITQBV-UHFFFAOYSA-N CC(C(C(OP([O-])[O-])=O)=C1C)=CC(C)=C1C1=CC=CC=C1.[Li+].[Li+] Chemical group CC(C(C(OP([O-])[O-])=O)=C1C)=CC(C)=C1C1=CC=CC=C1.[Li+].[Li+] VZLZTLCFXITQBV-UHFFFAOYSA-N 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 abstract description 5
- 206010016654 Fibrosis Diseases 0.000 abstract description 3
- 230000004761 fibrosis Effects 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 53
- 229920001436 collagen Polymers 0.000 description 21
- 206010052428 Wound Diseases 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000008439 repair process Effects 0.000 description 11
- 101100172132 Mus musculus Eif3a gene Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 230000002357 endometrial effect Effects 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229930189092 Notoginsenoside Natural products 0.000 description 7
- 235000002791 Panax Nutrition 0.000 description 7
- 241000208343 Panax Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- -1 oxygen free radical Chemical class 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000009759 San-Chi Substances 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 4
- 101710185487 Cysteine and glycine-rich protein 1 Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 208000002777 Gynatresia Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 3
- 102100031621 Cysteine and glycine-rich protein 2 Human genes 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940096422 collagen type i Drugs 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100027364 Cysteine-rich protein 3 Human genes 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 108010023942 cysteine and glycine-rich protein 3 Proteins 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 101100526762 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rpl-28 gene Proteins 0.000 description 1
- 101100362789 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rps-17 gene Proteins 0.000 description 1
- KHDZXBKJADQNKK-UHFFFAOYSA-N P(O)(O)O.C1(=CC=CC=C1)C=1C(=C(C(=O)[Li])C(=CC1C)C)C Chemical group P(O)(O)O.C1(=CC=CC=C1)C=1C(=C(C(=O)[Li])C(=CC1C)C)C KHDZXBKJADQNKK-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002831 nitrogen free-radicals Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides a preparation method of hydrogel with tissue repair and antioxidation functions and the hydrogel thereof, wherein the hydrogel is a solution comprising the following components: recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen, a solution of methacryloylated chitosan and total arasaponin containing a photoinitiator; the mass and volume concentration of the total saponins of panax notoginseng is not more than 0.6 percent. The hydrogel with tissue repair and antioxidation functions is suitable for various tissue repair, antibiosis and fibrosis prevention, and can simultaneously exhibit the functions of antioxidation and free radical removal.
Description
Technical Field
The invention relates to the field of materials, in particular to a preparation method of hydrogel with tissue repair and antioxidation functions and the hydrogel.
Background
The decrease of endometrial receptivity caused by the damage of endometrium due to congenital or acquired diseases, operation and the like is one of the main reasons for infertility of women of childbearing age. Uterine cavity adhesions (intrauterine adhesion, IUA), also known AS Asherman's Syndrome (AS), are usually caused by mechanical injuries such AS induced abortion surgery, uterine curettage or infections, and are manifested AS endometrial basal layer lesions, which in turn cause tissue adhesions and fibrosis, ultimately leading to reduced fertility.
The main clinical treatment method is hysteroscopic surgery treatment, namely, the adhesion part is separated through surgery, and the method has high recurrence rate and is easy to cause secondary damage. Drug infusion or oral drug therapy also suffers from significant drawbacks such as: the active ingredients are easy to lose, and the method is only suitable for immediate injury treatment and can not solve the subsequent healing and repairing problems; and also easily causes post-wound adhesion, wound infection, and the like.
Active oxygen aggregation and angiogenesis disorder can be caused after injury of a wound site, so that healing is difficult, oxygen free radical removal, inflammatory reaction inhibition and angiogenesis induction are key to treatment of the wound site, and therefore a novel material capable of resisting oxidation and scavenging free radicals is needed to better promote wound healing.
Disclosure of Invention
In order to solve the problems, the invention provides a preparation method of hydrogel with tissue repair and antioxidation functions, wherein the hydrogel is a solution comprising the following components: a solution of recombinant human type i collagen, recombinant human type iii collagen, or a mixture of recombinant human type i collagen and recombinant human type iii collagen, comprising a photoinitiator of methacryloylated chitosan and total arasaponin, said solution having a viscosity of 3000±3000 x 15% mpa.s to 15000±15000 x 15% mpa.s, preferably, said viscosity of 3000±3000 x 10% mpa.s to 15000±15000 x 10% mpa.s, more preferably, said viscosity of 3000±3000 x 5% mpa.s to 15000±15000 x 5% mpa.s when tested at a shear rate of 1/s; when the solution is applied to corresponding tissues, ultraviolet light or visible blue light is used for external irradiation, and the hydrogel is prepared after the solution becomes gel; the mass and volume concentration of the total saponins of panax notoginseng is not more than 0.6 percent, namely the mass of the total saponins of panax notoginseng in the 100ml solution is not more than 0.6: 0.6 g.
The human collagen is divided into more than 28 kinds of collagen according to different tissue parts, physiological functions and molecular structures, wherein the collagen is mainly type I collagen and type III collagen which are closely related to the skin injury repair process and repair quality, and the type I collagen is mainly present in adult skin, tendons and bone tissues from the distribution; type III collagen is mainly present in infant skin or in the intima and intestinal tract. The collagen type I and III in human body maintains the normal tissue structure of skin, forms an extracellular matrix network structure, plays roles in supporting organs and protecting organisms, and is also related to cell attachment and cell migration. The balance of the two also determines the hardness and tenderness of the skin, as well as the degree of wound healing and scarring. Therefore, when the recombinant human collagen is used in tissue repair, the type I collagen and the type III collagen can effectively promote repair and tissue regeneration.
In one embodiment, the total saponins of panax notoginseng mass volume concentration is 0.4% -0.6%.
In one embodiment, the photoinitiator is phenyl-2, 4, 6-trimethylbenzoyl lithium phosphite or (2-hydroxy-2-methyl-1- [4- (2-hydroxyethoxy) phenyl ] -1-propanone.
In one embodiment, the hydrogel has a viscosity of 10025.85 mPa-3163.85 mPa s when tested at 37 ℃ and a shear rate of 1/s.
In one embodiment, when the mass volume concentration of the methacryloylated chitosan is 8%, i.e., when the 100 ml solution contains 8 g methacryloylated chitosan, and when the mass volume concentration of the recombinant human type i collagen, the recombinant human type iii collagen, or the mixture of the recombinant human type i collagen and the recombinant human type iii collagen is 30%, i.e., when the 100 ml solution contains 30 g recombinant type i collagen, the recombinant human type iii collagen, or the mixture of the recombinant human type i collagen and the recombinant human type iii collagen, the volume ratio of the methacryloylated chitosan to the recombinant type i collagen, the recombinant human type iii collagen, or the mixture of the recombinant human type i collagen and the recombinant human type iii collagen is 3:1 to 1:1.
In one embodiment, the volume ratio of the methacryloylated chitosan to the recombinant human type i collagen, recombinant human type iii collagen, or a mixture of recombinant human type i collagen and recombinant human type iii collagen is 1:1, and the total saponins of panax notoginseng mass volume concentration is 0.6%.
In one embodiment, a hydrogel for controlling endometrial damage is provided, the hydrogel prepared by the method described above.
In one embodiment, a hydrogel for preventing and treating intrauterine adhesion and thin endometrium is provided, which is prepared by the above method.
In one embodiment, there is provided a hydrogel for preventing and treating intrauterine adhesion and thin endometrium, the hydrogel is a solution comprising recombinant human type i collagen, recombinant human type iii collagen, or a mixture of recombinant human type i collagen and recombinant human type iii collagen, methacryloylated chitosan containing a photoinitiator, and total saponins of panax notoginseng, and when the solution is applied to corresponding tissues, the hydrogel is prepared by externally irradiating with ultraviolet light or visible blue light, and stopping after the solution becomes gel-like; when the viscosity of the solution is tested under the conditions of 37 ℃ and a shear rate of 1/s, the viscosity is 3000 mPa & s-15000 mPa & s; the mass and volume concentration of the total saponins of panax notoginseng is not more than 0.6 percent, namely the mass of the total saponins of panax notoginseng in the 100 ml solution is not more than 0.6: 0.6 g.
In one embodiment, when the mass volume concentration of the methacryloylated chitosan is 8%, when the mass volume concentration of the recombinant human type i collagen, the recombinant human type iii collagen, or the mixture of the recombinant human type i collagen and the recombinant human type iii collagen is 30%, the volume ratio of the methacryloylated chitosan to the recombinant human type i collagen, the recombinant human type iii collagen, or the mixture of the recombinant human type i collagen and the recombinant human type iii collagen is 1:1 to 1:1, and the total mass volume concentration of the pseudo-ginseng saponin is 0.6%.
Tissue damage can occur in various organs or tissues of the human body, and generally includes external wounds, bacterial infections, surgical side effects, and the like. If not treated effectively in time, the wound may be infected, healed slowly, scar hyperplasia and even necrosis. The invention provides a preparation method of hydrogel with tissue repair and antioxidation functions and hydrogel thereof based on methacryloyl chitosan, collagen and panax notoginseng saponins, the material can be injected to corresponding tissues in a liquid state, can be photocrosslinked and solidified to form gel under the irradiation of ultraviolet light or visible light, can be firmly attached to wounds, promotes the wound healing, and can simultaneously exhibit the functions of resisting oxidation and scavenging free radicals. The invention can be applied to various tissue repair, antibiosis and prevention of fibrosis, including viscera injury repair, endometrium repair, cartilage repair, skin superficial repair and the like.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments described in the present application, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph showing the effect of a hydrogel of the present invention on repairing rat endometrial lesions.
Detailed Description
In order that those skilled in the art will better understand the technical solutions of the present application, the present application will be further described with reference to the following examples, and it is apparent that the described examples are only some, but not all, examples of the present application. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, shall fall within the scope of the application. The application is further described below with reference to the drawings and examples.
Example one preparation of the raw materials of the invention
Preparation of methacryloylated Chitosan (CSMA)
Adding chitosan powder into 0.1 mol/L acetic acid solution, wherein the mass volume fraction is as follows: 0.5 And (5%) to 5%, and stirring at normal temperature until the mixture is completely dissolved. The chitosan solution is placed in a water bath at 60 ℃, methacrylic anhydride is added dropwise, wherein the gram weight ratio of chitosan to methacrylic anhydride is 1:2-1:3. After the dripping is finished, stirring and reacting at 60 ℃ for 6-12 h. After the reaction was completed, 0.5 mol/L NaOH solution was slowly added dropwise to the reaction solution, and the pH of the reaction solution was adjusted to be neutral. The neutral reactant solution was dialyzed 72 h against deionized water, changing water once every 6: 6 h. The dialyzed solution is frozen at the temperature of minus 80 ℃ and then is freeze-dried in vacuum for 72 h, and the obtained freeze-dried powder product is the methacryloyl chitosan.
Preparation of recombinant human collagen type I or III (RC) solution
Dissolving recombinant human collagen type I or III powder in PBS buffer solution, and stirring at 37deg.C until completely dissolving.
Preparation of Panax Notoginseng Saponins (PNS) solution
Dissolving Notoginseng radix total saponin powder in PBS buffer solution, and stirring at room temperature until it is completely dissolved.
Preparation of a precursor solution of Tetramethacryloylated chitosan-collagen+Panax notoginsenosides hydrogel (Hydrogel)
The methacryloylated chitosan powder was taken and dissolved in PBS buffer, with the addition of 0.25% photoinitiator, and stirred at ambient temperature for 12h until complete dissolution. Then adding the collagen solution and the total arasaponin solution into the mixture, and stirring the mixture at the temperature of 4 ℃ in a dark place. Wherein, the mass volume concentration of the methacryloyl chitosan is 8% (w/v), the mass volume concentration of the collagen is 30% (w/v), and the mass volume concentration of the total sanchi saponin solution is 10% (w/v).
Fifth, hydrogel preparation method
When the methacryloylated chitosan-collagen+panax notoginseng saponins hydrogel precursor solution is used for repairing the injury, the solution is injected and filled into corresponding tissues, then ultraviolet light (365 nm) or visible blue light (405 nm) is used for irradiating the corresponding tissues externally, and the filled solution is stopped after the filled solution becomes gel. At this time, the hydrogel is highly adhered in gel form, preventing tissue adhesion; meanwhile, the repairing effect of various components can be better exerted, and the repairing and regenerating of damaged tissues can be promoted. The material and the application method are suitable for repairing various wounds, especially wounds with irregular shapes, such as epidermis injury, endometrium injury, cartilage regeneration, vaginal mucosa damage and the like, and can remove excessive free radicals at the oxidative stress part of the wound. The mixed solution can be changed from liquid to gel rapidly under irradiation of ultraviolet light (365 nm) or visible blue light (405 nm).
EXAMPLE two viscosity test of methacryloylated chitosan-collagen solution at different volume ratios
The methacryloyl Chitosan (CSMA) -collagen (RC) solutions with different volume ratios are dripped on a rheometer sample stage, and the viscosity test is carried out under the conditions of 37 ℃ and the shearing rate of 1/s.
TABLE 1 CSMA to RC solution viscosity at different ratios
According to viscosity detection data, the change of the volume ratio of the methacryloyl chitosan and the collagen can directly influence the viscosity of the solution, when the ratio of CSMA to RC is more than 3:1, the viscosity is lower than 3000 mPa & s, and the viscosity is lower, the fluidity is strong, and the solution is unfavorable for residence in the uterine cavity; when the ratio of CSMA to RC is smaller than 1:1, the viscosity is higher than 15000 mPa.s, the viscosity is larger, the injectable type is difficult to achieve, the damaged tissue is difficult to be completely covered, and the treatment effect cannot be achieved. Therefore, the solution viscosity is considered to be suitable for being used as a drug loading platform for subsequent experiments when CSMA is rc=1-3:1.
Example three experiments of loading Panax notoginsenosides with different ratios on cell compatibility of composite hydrogels
In the volume proportion CSMA, RC=1:1 of methacryloylated chitosan-collagen hydrogel precursor solution, 10% of total sanchi saponin solution with mass volume concentration is loaded in different proportions to form 10% of total sanchi saponin hydrogel precursor solution with mass volume concentration of 10% of total sanchi saponin solution with mass volume concentration of 2%, 4%, 6%, 8% and 10% of total 100ml of solution, namely the total 100ml of solution contains 2 ml, 4 ml, 6 ml, 8 ml and 10 ml of total sanchi saponin solution with mass volume concentration of 10%.
Each group of precursor solutions was injected into a six-well plate, and after sterilization by uv irradiation for 30min, methacryloylated chitosan-collagen + total arasaponin hydrogels (denoted as 2% hydrogel, 4% hydrogel, 6% hydrogel, 8% hydrogel, 10% hydrogel, respectively) were formed. Each set of hydrogels and DMEM complete broth (DMEM basal medium, 10% fetal bovine serum, and 1% diabody, which is streptomycin and penicillin) were placed in 50mL sterile centrifuge tubes to give samples with a hydrogel concentration of 0.1 g/mL, and the centrifuge tubes with the samples were placed in a 37 ℃ 5% CO 2 incubator for 72 h to give a hydrogel extract. Human endometrial stromal cells HESCs were seeded at a density of 1X 10 3/100. Mu.L of cell suspension per well in 96-well plates and cultured in a 5% CO 2 incubator at 37℃for 24h. The medium was aspirated and 200. Mu.L of the extract per well was added and set as the experimental group. While the control group was further incubated with 200. Mu.L of DMEM complete medium per well. Three time points of 24h, 48 h and 72 h were simultaneously cultured for each group and 5 duplicate wells were set for each time point. For the measurement, the old medium was discarded, 100. Mu.L of DMEM complete medium and 10. Mu.L of CCK8 solution were added to each well, the mixture was blown up uniformly, and the absorbance was measured at 450 nm using an microplate reader after incubation at 37℃for 1.5 h.
The calculation formula of the cell viability (Cell Viability) is as follows:
The calculated average cell viability is shown in the following table, and it is found from the data in the table that the cell viability of the 8% hydrogel group after 72h and the cell viability of the 10% hydrogel group after 48 h are less than 95%, so that the total saponins loading ratio of pseudo-ginseng is considered to be unsuitable for normal growth of cells and subsequent in vivo experiments.
Therefore, when the loading ratio of the total saponins of panax notoginseng is not more than 8%, the methacryloylated chitosan-collagen + total saponins of panax notoginseng hydrogel has good cell compatibility, is suitable for being used on wounds and is beneficial to wound healing.
TABLE 2 influence of hydrogels with different loading ratios of Panax notoginsenosides on cell viability
Example IV Effect of loading Panax notoginsenosides at different concentrations on the antioxidant capacity of hydrogels
Oxidative stress refers to a state in which highly active molecules such as active oxygen and active nitrogen radicals are produced excessively in the body when the body is subjected to various harmful stimuli, the oxidation degree exceeds the oxide scavenging ability, and the oxidation system and the antioxidant system are dynamically unbalanced, thereby causing damage to cells and tissues. Research shows that the oxidative stress caused by unbalanced level of oxidation and reduction in the organism is the pathophysiological basis of a plurality of diseases, and the oxidation stress is defended, and the oxidation resistance system in the organism is mainly relied on. DPPH, diphenyl picrylphenylhydrazine, is a stable nitrogen-centered chromogenic radical that produces a characteristic absorption peak at 515 nm wavelengths. The antioxidant substance in the sample can reduce the absorbance of DPPH until the absorbance disappears, and the change amount of the absorbance is in linear relation with the content of the antioxidant substance in a certain interval.
In the volume proportion CSMA, RC=1:1, the methacryloylated chitosan-collagen hydrogel precursor solution is loaded with several kinds of total arasaponin solutions in different proportions to form the methacryloylated chitosan-collagen+total arasaponin hydrogel precursor solution with different proportions, wherein the loading proportion of the total arasaponin solution is 2%, 4% and 6%.
Each set of precursor solutions was injected into a six-well plate, cured by uv irradiation and sterilized for 30 min a, forming methacryloylated chitosan-collagen + total saponins of panax notoginseng hydrogels (2% hydrogel, 4% hydrogel, 6% hydrogel, respectively). And taking out each group of hydrogel, quick-freezing for 1h in a refrigerator at the temperature of minus 80 ℃, and then placing the hydrogel into a freeze vacuum dryer for vacuum drying for 48-72 h to prepare freeze-dried samples. The dried sample of 0.1 g is placed at the bottom of a centrifuge tube, added with 1mL PBS buffer, placed in a 37 ℃ incubator for incubation of 0.5-1 h, and then the extract is taken out for centrifugation (6000 rmp, 10 min), and the supernatant is taken. DPPH reagent with concentration of 0.04 mg/mL is prepared. 950. Mu.L DPPH reagent and 50. Mu.L sample leach supernatant were added to the EP tube. A blank of 950. Mu.L DPPH reagent and 50. Mu.L PBS buffer was used, and a control of 950. Mu.L DPPH reagent and 50. Mu.L absolute ethanol was used. After thoroughly mixing, 100 μl was added to a 96-well plate, and detection was performed with an enzyme-labeled instrument at wavelength 515 nm, and OD values were recorded, with 5 replicate wells per group.
DPPH radical clearance = (OD blank-OD sample+od control)/OD blank 100%
The DPPH radical scavenging rate of each group is shown in the following table, and it is found that the average DPPH radical scavenging rate of the 2% hydrogel group is only 1.1904%, and the oxidation stress state of the wound part is hardly improved. The 4% hydrogel and the 6% hydrogel have remarkable free radical scavenging effect, and can largely defend against oxidative stress. Therefore, when the loading ratio of the total saponins of panax notoginseng is more than 4%, the composite hydrogel can have better antioxidation effect.
TABLE 3 hydrogel DPPH radical scavenging Rate for different Panax notoginsenosides loading ratios
Example four effects of hydrogels of methacryloylated chitosan-collagen on the repair Capacity of rat endometrial lesions
An endometrial injury repair experiment was established for rats, and female SD rats, 8 weeks old, weighing about 250 g, and sexually mature, were selected and adapted for one week. After the rats are anesthetized by isoflurane, the abdomen is prepared for skin, and the abdomen is cut off to find out the Y-shaped uterus. The upper and lower ends of the uterus are clamped by hemostatic clips respectively, a 1mL syringe is inserted into the uterus of a rat, 95% alcohol is injected into the uterus to be full, and the uterus is washed with physiological saline for several times after 60 s. At this time, the methacryloylated chitosan-collagen + panax notoginseng saponins hydrogel precursor solutions (CRP 1, CRP2, CRP 3) at different concentrations were injected into the injured uterus, and then externally irradiated with ultraviolet light or blue light at about 60 s, which was seen to be gel-like. And (5) sterilizing after suturing, and continuing feeding for observation. An alcohol damage Control group (designated as Control) was also set. All rats were sacrificed 7 days post-surgery, uterine tissue was photographed and fixed in 4% paraformaldehyde at 48 h, and then observed after ethanol gradient dehydration, paraffin embedding, and slice staining.
As shown in figure 1, the uterus of the alcohol damage control group can be obviously blood stasis, and each group of uterus of CRP1, CRP2 and CRP3 has no obvious wound, and has little material residue in the uterus and is gel. From the H & E staining results, the rat uterine epithelium after alcohol injury is lost, the number of matrix cells is small, the matrix cells are loosely arranged, the rat uterine epithelium presents thin intima symptoms, and the repairing effect is poor. The CRP1, CRP2 and CRP3 have the advantages of repairing each group to a certain extent, increasing the endometrium thickness, increasing the number of matrix cells, and completely coating obvious glands and uterine cavity epithelium. Among them, CRP1 group repair effect was more remarkable. The results show that the CRP1 group, namely CSMA: RC=1:1, and the methacryloylated chitosan-collagen+Panax notoginsenosides hydrogel loaded with 6% of Panax notoginsenosides has good antioxidant capacity and also has the capacity of promoting endometrial injury repair and wound healing.
It is to be understood that this invention is not limited to the particular methodology, protocols, and materials described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also encompassed by the appended claims.
Claims (9)
1. A solution for preparing a hydrogel with tissue repair and antioxidant functions, wherein the solution for preparing the hydrogel is a solution comprising: recombinant human type I collagen, recombinant human type III collagen or a mixture of recombinant human type I collagen and recombinant human type III collagen, a solution of methacryloylated chitosan and total saponins of panax notoginseng containing a photoinitiator, wherein the viscosity is 3000 mPa-15000 mPa-s when the solution is subjected to viscosity test under the conditions of 37 ℃ and a shear rate of 1/s; when the solution is applied to corresponding tissues, ultraviolet light or visible blue light is used for external irradiation, and the hydrogel is prepared after the solution becomes gel; the mass and volume concentration of the total saponins of panax notoginseng is 0.4% -0.6%.
2. The solution according to claim 1, wherein the photoinitiator is lithium phenyl-2, 4, 6-trimethylbenzoyl phosphite or 2-hydroxy-2-methyl-1- [4- (2-hydroxyethoxy) phenyl ] -1-propanone.
3. The solution according to claim 1, wherein the viscosity is 10025.85 mPa-3163.85 mPa s when the solution is subjected to a viscosity test at 37 ℃ at a shear rate of 1/s.
4. The solution of claim 1, wherein the 100ml solution comprises 8g methacryloylated chitosan and the 100ml solution comprises 30 g recombinant human type i collagen, recombinant human type iii collagen, or a mixture of recombinant human type i collagen and recombinant human type iii collagen when the mass volume concentration of the recombinant human type i collagen, recombinant human type iii collagen, or a mixture of recombinant human type i collagen and recombinant human type iii collagen is 30%, and the volume ratio of the methacryloylated chitosan to the recombinant human type i collagen, recombinant human type iii collagen, or a mixture of recombinant human type i collagen and recombinant human type iii collagen is 3:1 to 1:1.
5. The solution according to claim 4, wherein the volume ratio of the methacryloylated chitosan to the recombinant human type i collagen, recombinant human type iii collagen, or a mixture of recombinant human type i collagen and recombinant human type iii collagen is 1:1, and the total saponins of panax notoginseng mass volume concentration is 0.6%.
6. A hydrogel for preventing and treating endometrium injury, wherein the hydrogel is prepared by externally irradiating the solution according to any one of claims 1 to 5 with ultraviolet light or visible blue light, and stopping the application after the solution becomes gel-like.
7. A hydrogel for preventing and treating intrauterine adhesion and thin endometrium, characterized in that when the solution according to any one of claims 1-5 is applied to the corresponding tissue, the solution is irradiated with ultraviolet light or visible blue light from outside and stopped after the solution becomes gel-like, thus preparing the hydrogel.
8. The hydrogel for preventing and treating intrauterine adhesion and thin endometrium is characterized in that the solution for preparing the hydrogel comprises recombinant human type I collagen, recombinant human type III collagen or a mixture of the recombinant human type I collagen and the recombinant human type III collagen, a solution containing a photoinitiator, methacryloylated chitosan and total saponins of pseudo-ginseng, when the solution is applied to corresponding tissues, ultraviolet light or visible blue light is used for irradiation outside, and the hydrogel is prepared after the solution becomes gel; when the solution is subjected to viscosity test under the conditions of 37 ℃ and a shearing rate of 1/s, the viscosity is 3000 mPa.s-15000 mPa.s, and the mass and volume concentration of the total saponins of panax notoginseng is 0.4-0.6%.
9. The hydrogel of claim 8, wherein when the methacryloylated chitosan has a mass to volume concentration of 8%, the methacryloylated chitosan and the recombinant human type i collagen, the recombinant human type iii collagen, or the mixture of the recombinant human type i collagen and the recombinant human type iii collagen has a mass to volume concentration of 30%, the ratio of the methacryloylated chitosan to the recombinant human type i collagen, the recombinant human type iii collagen, or the mixture of the recombinant human type i collagen and the recombinant human type iii collagen is 1:1, and the total saponins of panax notoginseng has a mass to volume concentration of 0.6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411241750.8A CN118750659B (en) | 2024-09-05 | 2024-09-05 | Preparation method of hydrogel with tissue repair and antioxidation functions and hydrogel thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411241750.8A CN118750659B (en) | 2024-09-05 | 2024-09-05 | Preparation method of hydrogel with tissue repair and antioxidation functions and hydrogel thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118750659A CN118750659A (en) | 2024-10-11 |
| CN118750659B true CN118750659B (en) | 2024-11-15 |
Family
ID=92945951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411241750.8A Active CN118750659B (en) | 2024-09-05 | 2024-09-05 | Preparation method of hydrogel with tissue repair and antioxidation functions and hydrogel thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118750659B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119055827B (en) * | 2024-10-30 | 2025-01-24 | 南京工业大学 | Carboxylated chitosan hydrogel dressing containing recombinant humanized I/III type collagen microgel and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897990A (en) * | 2010-07-06 | 2010-12-01 | 大连理工大学 | Dressing composition used for inhibiting scars and accelerating wound healing and application thereof |
| CN111202695A (en) * | 2020-01-14 | 2020-05-29 | 深圳市福美富基因科技有限公司 | Natural edible composition with health care function, application thereof, makeup cosmetic and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| EP2451484A4 (en) * | 2009-07-09 | 2014-05-07 | Polymers Crc Ltd | Biopolymer hybrid gel-depot delivery system |
| US20240150820A1 (en) * | 2021-03-11 | 2024-05-09 | Chemometec A/S | Assessment of biological particles immobilized in a hydrogel |
| CN115624558A (en) * | 2021-11-16 | 2023-01-20 | 右江民族医学院附属医院 | Research on action mechanism of panax notoginseng saponins to cerebral ischemia and application of technical method thereof in traditional Chinese medicine development |
| WO2023172748A2 (en) * | 2022-03-10 | 2023-09-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Formulation for wound healing |
-
2024
- 2024-09-05 CN CN202411241750.8A patent/CN118750659B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897990A (en) * | 2010-07-06 | 2010-12-01 | 大连理工大学 | Dressing composition used for inhibiting scars and accelerating wound healing and application thereof |
| CN111202695A (en) * | 2020-01-14 | 2020-05-29 | 深圳市福美富基因科技有限公司 | Natural edible composition with health care function, application thereof, makeup cosmetic and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118750659A (en) | 2024-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kong et al. | 5-hydroxymethylfurfural-embedded poly (vinyl alcohol)/sodium alginate hybrid hydrogels accelerate wound healing | |
| CN110339393B (en) | A kind of wound dressing based on hydrogel-core-shell microspheres and preparation method thereof | |
| CN113509590B (en) | Wound dressing with exosome combined with hyaluronic acid and preparation method and application thereof | |
| KR20040068172A (en) | A Pharmaceutical Composition for Treatment of Wounds Containing Blood Plasma or Serum | |
| CN118750659B (en) | Preparation method of hydrogel with tissue repair and antioxidation functions and hydrogel thereof | |
| KR20100093516A (en) | Surgical hydrogel | |
| Hu et al. | Minimally invasive delivery of human umbilical cord-derived mesenchymal stem cells by an injectable hydrogel via Diels–Alder click reaction for the treatment of intrauterine adhesions | |
| CN111956611A (en) | Curcumin-loaded nano micelle and preparation method and application thereof | |
| CN116763724B (en) | Preparation method of recombinant collagen hydrogel loaded with curcumin and application of recombinant collagen hydrogel in uterine cavity adhesion treatment | |
| CN106039416A (en) | Chitosan-sericin composite biological scaffold as well as preparation method and application thereof | |
| CN112274691A (en) | Preparation method and application of wound dressing difficult to heal and loaded with magnetic exosomes | |
| Chen et al. | A novel wound dressing based on a gold nanoparticle self-assembled hydrogel to promote wound healing | |
| CN118718128B (en) | Preparation method of hydrogel with tissue repair and fiber prevention functions and hydrogel thereof | |
| CN115919751A (en) | Preparation method and application of recombinant collagen hydrogel | |
| CN115969772A (en) | A kind of preparation method and application of thermosensitive hydrogel | |
| CN115887744A (en) | Drug-loaded liposome hydrogel and preparation and application thereof | |
| CN110812526A (en) | A kind of PRP-chitosan-silk fibroin composite material and preparation method thereof | |
| US20250135070A1 (en) | Hyaluronic acid-based hydrogel precursor solution, hyaluronic acid-based hydrogel and repair material thereof | |
| CN117899267A (en) | Preparation method of collagen drug-loaded sponge for repairing osteoporotic bone defects | |
| CN115518191B (en) | Preparation method of medical dressing capable of promoting wound to quickly stop bleeding | |
| CN118141974A (en) | A silk fibroin accumulation particle capable of rapid hemostasis | |
| CN118750660B (en) | Preparation method of photosensitive wound damage repair hydrogel and hydrogel thereof | |
| Repciuc et al. | Management of surgical wound dehiscence by oxygen-ozone therapy in a FIV-positive cat–A case report | |
| RU2252787C1 (en) | Method for obtaining artificial skin matrix | |
| CN114432493B (en) | Injectable biodegradable temperature-sensitive hydrogel and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |